Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study- few concerns

Area of Science:

• Pulmonology
• Pharmacology

Background:

• A previous study by Ahmed et al. compared Fluticasone/salmeterol combination therapy with salbutamol.
• The study concluded that the combination therapy increased FEV1, FEV1% of predicted, and FEV1/FVC ratio compared to salbutamol.

Discussion:

• This response letter argues that the findings by Ahmed et al. lack novelty.
• Both salbutamol and the Fluticasone/salmeterol combination met established reversibility benchmarks (12% and 200 mL).
• Concerns are raised regarding the routine incorporation of inhaled corticosteroids (ICS) in combination therapies, as ICS are not primarily bronchodilators.

Key Insights:

• The efficacy of Fluticasone/salmeterol over salbutamol in improving lung function metrics was observed.
• Established reversibility benchmarks were met by both treatment groups, questioning the significance of the observed differences.
• The pharmacological rationale for combining an ICS with a bronchodilator warrants further consideration.

Outlook:

• Further research is needed to clarify the role and optimal use of combination inhalers containing ICS and long-acting beta-agonists.
• Clinical guidelines may need re-evaluation regarding the combination of bronchodilators and ICS.
• Investigating the specific mechanisms and long-term benefits of such combinations in various respiratory conditions is essential.